Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment

Journal of Viral Hepatitis

Volumn 22, Issue 1, 2014, Pages 8-17

  Aggarwal, J ^a   Vera Llonch, M ^b   Donepudi, M ^b   Suthoff, E ^b   Younossi, Z ^c   Goss, T F ^a  

^a Boston Healthcare Assoc Inc   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Employment; Hepatitis C; Patient reported outcomes; Telaprevir; Work productivity

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ABSENTEEISM; ADULT; ANTIVIRAL THERAPY; ARTICLE; DEMOGRAPHY; EMPLOYMENT STATUS; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL HEALTH; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRESENTEEISM; PRIORITY JOURNAL; PRODUCTIVITY; QUESTIONNAIRE; SELF REPORT; TREATMENT DURATION; UNEMPLOYMENT; WORK; WORK PRODUCTIVITY QUESTIONNAIRE; WORKING TIME; AGED; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EFFICIENCY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; QUESTIONNAIRES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84926137368     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12227     Document Type: Article

References (24)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31(8):1090-1101.
2. Hepatitis C. [Fact sheet no 164 June 2012] [Internet]. Switzerland: World Health Organization, 2012. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 16 July 2013)
3. Hepatitis C FAQs for the public [Internet]. Georgia: Centers for Disease Control and Prevention, 2012. Available at: http://www.cdc.gov/hepatitis/c/cfaq.htm (accessed 16 July 2013)
4. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45(2):e17-e24.
5. Su J, Brook RA, Kleinman NI, Corey-Lisle P. The impact of hepatitis c virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010;52(2):436-442.
6. DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Kim WR. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011;14(2):253-261.
7. Brook RA, Kleinman NL, Su J, Coreyl-Lisle PK, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011;17(10):657-664.
8. John-Baptiste AA, Tomlinson G, Hsu PC et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009;104(10):2439-2448.
9. Perrillo R, Rothstein KD, Rubin R et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004;11(2):157-165.
10. McHutchison JG, Ware JE, Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-147.
11. ™ [US Prescribing Information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2013.
12. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
13. Jacobson I, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-2416.
14. Kleinman L, Zodet MW, Hakim Z et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508.
15. Thal G, Nuyts G, McCallister S et al. Work productivity among genotype 1 hepatitis C virus (HCV) treatmentn aïve patients receiving telaprevirbased treatment regimens: results from ADVANCE and ILLUMINATE Studies. Presented at 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD, USA, 2011.
16. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-212.
17. Hassanein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004;40:675-681.
18. Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003;21:341-349.
19. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL, The International Hepatitis Interventional Therapy Group. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30:550-555.
20. QuickStats: Average Number of Work-Loss Days During the Preceding 12 Months Among Persons Aged 18-64 by Age Group and Sex [Internet]. Georgia: Centers for Disease Control and Prevention, 2009. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5830a5. htm (accessed 16 July 2013)
21. Shaefer M, Capuron L, Friebe A et al. Hepatitis c infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012;57(6):1379-1390.
22. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007;45:806-816.
23. Muir AJ, Sherman KE, Aggarwal J et al. Predictors of fatigue severity among treatment-näive genotype 1 chronic hepatitis C patients: Posthoc analysis of data from ADVANCE and ILLUMINATE. Poster Presented at the American College of Gastroenterology Annual Scientific Meeting. October 19-24, Las Vegas, Nevada.
24. Lusinyan L, Bonato L. Work absence in Europe. IMF Staff Pap 2007;54(3):475-538.